BridgeBio Pharma (BBIO) Gross Profit (2020 - 2026)

BridgeBio Pharma (BBIO) has 7 years of Gross Profit data on file, last reported at $184.6 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 61.92% year-over-year to $184.6 million; the trailing twelve-month figure through Mar 2026 stood at $551.7 million (up 354.09% YoY), and the FY2025 full-year result was $481.1 million, up 120.67% from the prior year.
• Gross Profit improved to $184.6 million in Q1 2026, from $146.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $210.5 million in Q1 2024 to a low of -$401000.0 in Q3 2022.
• A 5-year average of $56.8 million and a median of $3.5 million in 2023 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit sank 145.06% in 2022 and soared 17816.77% in 2024, its largest moves.
• Tracing BBIO's Gross Profit over 5 years: stood at $1.2 million in 2022, then declined by 6.21% to $1.1 million in 2023, then soared by 231.12% to $3.8 million in 2024, then jumped by 3746.0% to $146.1 million in 2025, then gained by 26.36% to $184.6 million in 2026.
• Business Quant data shows BBIO's Gross Profit at $184.6 million in Q1 2026, $146.1 million in Q4 2025, and $114.1 million in Q3 2025.